CYTEA BIO is a pre-clinical stage biotech company developing therapeutic products by combining genetically unmodified effector cells and engineered targeting ligands. Its patented Pin™ Platform enables practically limitless combinations of effector mechanisms and targeting ligands for applications in oncology and immunology. CYTEA BIO is the first portfolio company of MedXCell, a European cell therapy venture builder with offices in Switzerland, France and the US. MedXCell focuses on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders, with the aim to turn promising academic ideas into commercially viable propositions.
Company Details
- Employees
- 9
- Address
- Montpellier, Fr
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://cytea.bio
- Keywords
- Biotech, Cell Therapy, NK cells, Antibody, Macrophages, Manufacturing, Pharmaceutical Product Development.
- HQ
- Montpellier
Cytea Bio Questions
Cytea Bio's website is https://cytea.bio
Cytea Bio's LinkedIn profile is https://fr.linkedin.com/company/cytea-bio
Cytea Bio has
9 employees.
View email and phone details for 9
employees at Cytea Bio.
Cytea Bio's industry is
Biotechnology Research
Cytea Bio's top competitors are
Ai-Biopharma,
Lytix Biopharma,
Orinova,
Recobia Therapeutics,
Apmonia Therapeutics,
Yomi Pharma,
Medxcell Sa,
Oncovita,
React Therapeutics,
Infocus Therapeutics.
Cytea Bio's categories are Biotechnology Research
